BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.
UBS Global Healthcare Conference
Wednesday, November 13, 2024
Terranea Resort, Rancho Palos Verdes, CA
David Roberts, President, will present at 7:15 AM PT
Stifel's 2024 Healthcare Conference
Tuesday, November 19, 2024
Lotte NY Palace Hotel, New York City
David Roberts, President, will present at 1:50 PM ET
Wolfe Research Healthcare Conference 2024
Wednesday, November 20, 2024
Wolfe Research HQ, New York City
David Roberts, President, will present at 2:00 PM ET
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
| Last Trade: | US$92.12 |
| Daily Change: | -0.13 -0.14 |
| Daily Volume: | 367,631 |
| Market Cap: | US$2.070B |
December 16, 2024 October 31, 2024 August 01, 2024 May 02, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
